Isolated oculomotor nerve palsy is a relatively uncommon symptom of pituitary adenoma that usually occurs in association with pituitary apoplexy or cavernous sinus (CS) invasion. We report two cases of relatively small pituitary adenomas with neither apoplexy nor CS invasion presenting as isolated oculomotor nerve palsy. Both patients presented with gradually worsening diplopia, without headache or visual field defects. Magnetic resonance imaging (MRI) showed a pituitary tumor with no evidence of intratumoral hemorrhage. Computed tomography revealed a lateroposterior extension of the tumor with the erosion of the posterior clinoid process. Constructive interference in steady-state MRI revealed compression of the oculomotor nerve by the tumor at the oculomotor triangle. The patients underwent endoscopic transsphenoidal surgery, and the intraoperative findings showed that the tumors did not invade the CS. The tumors were completely resected, and the oculomotor palsies resolved fully. These cases illustrate the need to consider isolated oculomotor nerve palsy as an initial manifestation of a relatively small pituitary adenoma with neither apoplexy nor CS invasion. Based on the characteristic radiological findings, early surgical treatment is recommended to preserve oculomotor function.
Background/Objectives: World Health Organization (WHO) Grade 2–3 meningiomas have high recurrence rates despite postoperative radiotherapy. This study aimed to characterize patterns of failure and clinical outcomes after postoperative external beam radiotherapy. Methods: We retrospectively analyzed 10 patients with WHO Grade 2 (n = 6) or Grade 3 (n = 4) meningiomas treated at a single institution between January 2017 and May 2024. Nine patients underwent gross total resection. Radiotherapy was delivered using three-dimensional conformal radiotherapy (n = 6) or intensity-modulated radiotherapy (n = 4), with a median dose of 60 Gy in 30 fractions. Recurrence patterns were assessed relative to the high-dose region. Results: The 1- and 3-year overall survival rates were 90% (95% CI, 47–99%) and 79% (95% CI, 38–94%), respectively; corresponding local control rates were 70% (95% CI, 33–89%) and 39% (95% CI, 7–71%), respectively. Recurrence occurred in six patients, predominantly within the high-dose region. Acute toxicities were limited to Grade 1 radiation dermatitis. During follow-up, Grade 3 seizures occurred in three patients, and worsening of pre-existing Grade 2 paresis occurred in four patients. Two seizure events and two cases of worsening paresis were considered more likely related to recurrent or progressive disease, whereas attribution of the remaining neurological events to radiotherapy was uncertain. Conclusions: Despite postoperative radiotherapy, local control remained limited in this small, single-institution series, with a predominance of in-field recurrence. This pattern raises the possibility that tumor biological factors, in addition to technical and treatment-related factors, may contribute to treatment failure in WHO Grade 2–3 meningiomas. These findings are exploratory and warrant validation in larger studies incorporating molecular stratification and standardized treatment approaches.